AnaptysBio (NASDAQ:ANAB) Posts Quarterly Earnings Results, Beats Estimates By $0.89 EPS

AnaptysBio (NASDAQ:ANAB) issued its earnings results on Thursday. The biotechnology company reported ($0.72) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.61) by $0.89, Zacks reports. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The firm had revenue of $43.11 million during the quarter, compared to analyst estimates of $10.17 million.

AnaptysBio Stock Down 1.2 %

Shares of AnaptysBio stock traded down $0.19 during trading on Friday, reaching $16.21. The company’s stock had a trading volume of 128,912 shares, compared to its average volume of 1,064,702. AnaptysBio has a 52-week low of $12.21 and a 52-week high of $41.31. The firm’s 50-day moving average is $15.96 and its two-hundred day moving average is $24.83. The company has a market cap of $493.19 million and a price-to-earnings ratio of -2.67.

Insider Buying and Selling

In related news, Director Ecor1 Capital, Llc purchased 65,184 shares of AnaptysBio stock in a transaction that occurred on Monday, December 30th. The shares were acquired at an average cost of $12.92 per share, for a total transaction of $842,177.28. Following the transaction, the director now directly owns 7,860,180 shares in the company, valued at $101,553,525.60. The trade was a 0.84 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 33.70% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on ANAB shares. HC Wainwright reiterated a “neutral” rating and issued a $19.00 price target on shares of AnaptysBio in a research report on Tuesday, February 4th. Wedbush restated an “outperform” rating and set a $40.00 price target on shares of AnaptysBio in a research report on Wednesday, February 12th. JPMorgan Chase & Co. decreased their price target on shares of AnaptysBio from $66.00 to $36.00 and set an “overweight” rating on the stock in a report on Thursday, December 19th. Truist Financial dropped their price objective on AnaptysBio from $30.00 to $20.00 and set a “hold” rating for the company in a research note on Wednesday, December 18th. Finally, Wolfe Research began coverage on AnaptysBio in a research note on Tuesday, February 4th. They issued an “outperform” rating and a $25.00 target price on the stock. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $34.11.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.